The North America Blood Group Typing Market is expected to witness robust growth over the forecast period, driven by technological advancements and rising demand in healthcare settings. The market size was valued at USD 1,360 Million in 2025 and is projected to reach USD 2,890 Million by 2035, growing at a CAGR of 6.9% between 2024 and 2035.
The economic impact of tariffs on "North America Blood Group Typing Market".
Market Growth Drivers
Technological advancements in molecular diagnostics and automation are fueling the growth of blood group typing in North America. Companies like Bio-Rad Laboratories have introduced automated blood typing analyzers that provide rapid and highly accurate results, significantly reducing turnaround time in diagnostics. This enhances blood safety in transfusions and surgical procedures, aligning with the increasing need for precision medicine and efficient patient management.
Rising incidence of chronic diseases and a growing number of surgical procedures are generating a significant demand for blood transfusion services in the region. For example, Ortho Clinical Diagnostics has partnered with major hospital networks to deploy high-throughput instruments for blood typing, supporting emergency response and routine care. This demand is further augmented by awareness campaigns conducted by organizations such as the American Red Cross, emphasizing the importance of blood donation and compatibility testing.
Market Trends
Adoption of point-of-care testing (POCT) for blood group typing is becoming increasingly popular in North America. Companies like QuidelOrtho are rolling out portable, easy-to-use blood typing devices that deliver quick results at the bedside or in mobile clinics. This trend supports efficient emergency care and broadens access to blood typing in rural and resource-limited settings, significantly improving patient outcomes.
Integration of artificial intelligence (AI) and machine learning algorithms into blood group typing platforms is transforming laboratory operations. Terumo Blood and Cell Technologies has explored AI-driven software that assists in the analysis and interpretation of complex blood group profiles. This not only streamlines workflow in clinical labs but also minimizes human error, enhancing the reliability of transfusion services across the region.
Market Opportunity
Expansion of precision medicine programs in the US and Canada presents opportunities for companies to develop advanced genotyping assays. Thermo Fisher Scientific is actively working on supporting personalized transfusion practices through next-generation sequencing technologies.
Increasing collaborations between biotech firms and research institutes, such as the recent partnership between Immucor and Canadian Blood Services, provide a platform for launching innovative blood group typing solutions tailored to local needs.
North America Blood Group Typing Market Revenue (USD Million), 2020-2035
The chart illustrates a progressive increase in market revenue from 2020 to 2035. The revenue rose from USD 800 Million in 2020 to USD 1,360 Million by 2025, reflecting expanding adoption, especially in hospital and transfusion settings. From 2026 onwards, the compound annual growth rate sustains momentum, with the market projected to achieve USD 2,890 Million by 2035. This consistent growth trend highlights the ongoing demand for advanced blood group typing solutions, driven by technological innovation, personalized healthcare, and improved disease burden management across North America.
Market Share by Region, 2025
The pie chart depicts the distribution of market share for blood group typing in North America in 2025. The United States holds the major share at 72%, followed by Canada at 18%, and Mexico at 6%. Other regions, including the Caribbean and Central America (4%), constitute the remainder. These figures reflect the dominance of the US in terms of healthcare infrastructure and technology adoption, while Canada also maintains a strong presence due to its organized blood transfusion networks. Emerging contributions from Mexico and other regions are expected to grow as investment in healthcare and diagnostics increases.
Recent Developments
In March 2024, Ortho Clinical Diagnostics launched its new blood group genotyping assay, VITROS XT, in collaboration with several US hospital networks. This platform enables high-throughput, molecular-level typing, catering to complex clinical cases. By automating part of the workflow, the solution addresses labor shortages in healthcare and enhances transfusion safety. The company reports a positive uptake, suggesting increased efficiency and reduced turnaround times for critical blood profile matching.
In May 2024, Bio-Rad Laboratories received FDA clearance for its IH-1000 automated blood typing system. This instrument is designed for both large and mid-sized hospitals and is equipped with barcode management, auto sampling, and advanced software integration. Bio-Rad’s new launch facilitates compliance with stringent regulatory standards while easing the burden on laboratory staff. The development is part of their broader strategy to expand their diagnostics portfolio in North America.
June 2024 saw a partnership agreement between Thermo Fisher Scientific and Canadian Blood Services to develop next-generation sequencing-based blood group typing tests. Combining Thermo Fisher’s expertise in genomics with Canadian Blood Services’ clinical insights, this collaboration aims to create more accurate and high-throughput solutions for donor screening and transfusion compatibility. The project supports ongoing innovation and reflects the industry’s movement toward personalized medicine and population-based blood group data.
Press Releases